Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

This study provides a comprehensive evaluation of the off-target effects of ADARdd and provides guidelines for improving RNA editing accuracy in plants. The authors also emphasize that ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...